Bausch maintained its revenue guidance for full-year 2018 while raising the outlook for adjusted EBITDA. The company expects revenues to be $8.15 billion to $8.35 billion. Adjusted EBITDA is now expected to come in at $3.20 billion to $3.35 billion in 2018 versus the prior range of $3.15 billion to $3.30 billion.
During the quarter, the company completed its name change to Bausch Health Companies Inc. and realigned into four reporting segments – Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.
Bausch Health saw revenue declines across all its segments expect Salix. Revenues in Salix grew 14% mainly driven by higher sales of XIFAXAN, RELISTOR and other promoted products across the segment. XIFAXAN revenue grew 26% while RELISTOR franchise revenue rose 43% during the quarter. Revenue in the Global Solta business improved by 14% during Q2 2018.
The FDA accepted the New Drug Application for loteprednol etabonate ophthalmic gel with a PDUFA action date of February 25, 2019.
Related: Earnings Preview: Bausch Health looks for cure in Q3
Related: Q1 Earnings Infographic
